文献速递流行病学与生物统计

儿童和青少年糖尿病前期与2型糖尿病筛查:美国预防服务工作组证据报告与系统综述

Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2022-01-01

本系统综述旨在为美国预防服务工作组(USPSTF)提供证据,评估对儿童和青少年进行糖尿病前期和2型糖尿病筛查的获益与危害。检索截至2022年7月22日,纳入8篇出版物(856名参与者,平均年龄14岁),未发现直接评估筛查获益或危害的研究;针对糖尿病前期或近期诊断(非筛查发现)的糖尿病青少年,仅有的试验报告了少数健康结局且组间无差异,但证据受限于不精确性和随访时间可能不足以评估健康结局。

要点

  • 未发现直接评估儿童青少年糖尿病前期和2型糖尿病筛查获益或危害的研究。
  • 在近期诊断(非筛查发现)的糖尿病青少年中,仅有的试验报告了少数健康结局且组间无差异。
  • 证据受限于不精确性和随访时间可能不足以评估健康结局。

核心结论

  • 未发现直接评估儿童和青少年糖尿病前期和2型糖尿病筛查获益或危害的合格研究。
  • 对于糖尿病前期或近期诊断(非筛查发现)的糖尿病青少年,仅有的合格试验报告了少数健康结局且组间无差异,但证据受限于不精确性和随访时间可能不足以评估健康结局。

研究设计与样本

  • 系统综述检索PubMed/MEDLINE、Cochrane图书馆和试验注册库至2021年5月3日,并通过参考文献、专家和文献监测至2022年7月22日。
  • 纳入评估筛查或干预措施(针对筛查发现或近期诊断的糖尿病前期或2型糖尿病)的英文对照研究,由两人独立审查摘要、全文和研究质量,并进行定性综合。
  • 共纳入8篇出版物(856名参与者;平均年龄14岁,范围10-17岁),其中6篇来自TODAY研究。

主要发现

  • 无合格研究直接评估筛查的获益或危害。
  • 一项随机临床试验(TODAY;n=699名肥胖青少年;平均年龄14岁)比较二甲双胍、二甲双胍加罗格列酮和二甲双胍加生活方式干预,报告近期诊断糖尿病的青少年中分别有0、1、1例出现肾功能损害(P > .99),分别有5、3、3例发生糖尿病酮症酸中毒(P = .70)。
  • 一项随机临床试验(75名肥胖伴糖尿病前期青少年;平均年龄13岁)比较强化生活方式干预与标准护理,报告两组均无参与者发展为糖尿病,但随访仅6个月。
  • 在TODAY研究中,二甲双胍加罗格列酮组轻微低血糖事件发生率高于二甲双胍组或二甲双胍加生活方式干预组(8.2% vs 4.3% vs 3.4%,P = .05);重大低血糖事件报告率低于1%。
  • 在一项研究中,服用二甲双胍者比服用安慰剂者更常报告胃肠道不良事件(腹痛:25% vs 12%;恶心/呕吐:17% vs 10%;P未报告)。

局限性

  • 证据受限于不精确性和随访时间可能不足以评估健康结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Of youths diagnosed with type 2 diabetes, many develop microvascular complications by young adulthood. OBJECTIVE: To review the evidence on benefits and harms of screening children and adolescents for prediabetes and type 2 diabetes to inform the US Preventive Services Task Force (USPSTF). DATA SOURCES: PubMed/MEDLINE, Cochrane Library, and trial registries through May 3, 2021; references; experts; literature surveillance through July 22, 2022. STUDY SELECTION: English-language controlled studies evaluating screening or interventions for prediabetes or type 2 diabetes that was screen detected or recently diagnosed. DATA EXTRACTION AND SYNTHESIS: Dual review of abstracts, full-text articles, and study quality; qualitative synthesis of findings. MAIN OUTCOMES AND MEASURES: Mortality, cardiovascular morbidity, diabetes-related morbidity, development of diabetes, quality of life, and harms. RESULTS: This review included 8 publications (856 participants; mean age, 14 years [range, 10-17 years]). Of those, 6 were from the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study. No eligible studies directly evaluated the benefits or harms of screening. One randomized clinical trial (RCT) (TODAY; n = 699 adolescents with obesity; mean age, 14 years) comparing metformin, metformin plus rosiglitazone, and metformin plus lifestyle intervention reported that 2 youths with recently diagnosed diabetes developed kidney impairment (0 vs 1 vs 1, respectively; P > .99) and 11 developed diabetic ketoacidosis (5 vs 3 vs 3, respectively; P = .70). One RCT of 75 adolescents (mean age, 13 years) with obesity with prediabetes compared an intensive lifestyle intervention with standard care and reported that no participants in either group developed diabetes, although follow-up was only 6 months. Regarding harms of interventions, 2 RCTs assessing different comparisons enrolled youths with recently diagnosed diabetes. Major hypoglycemic events were reported by less than 1% of participants. Minor hypoglycemic events were more common among youths treated with metformin plus rosiglitazone than among those treated with metformin or metformin plus lifestyle intervention in TODAY (8.2% vs 4.3% vs 3.4%, P = .05). In 1 study, gastrointestinal adverse events were more commonly reported by those taking metformin than by those taking placebo (abdominal pain: 25% vs 12%; nausea/vomiting: 17% vs 10%; P not reported). CONCLUSIONS AND RELEVANCE: No eligible studies directly evaluated the benefits or harms of screening for prediabetes and type 2 diabetes in children and adolescents. For youths with prediabetes or recently diagnosed (not screen-detected) diabetes, the only eligible trials reported few health outcomes and found no difference between groups, although evidence was limited by substantial imprecision and a duration of follow-up likely insufficient to assess health outcomes.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Jonas DE, Vander Schaaf EB, Riley S, et al. Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2022. PMID: 36098720. doi:10.1001/jama.2022.7957

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。